Van ECK Associates Corp Purchases 11,354 Shares of Repligen Corporation $RGEN

Key Points

• Van ECK Associates increased its Repligen stake by 173.8% in the second quarter, purchasing 11,354 additional shares and bringing its holdings to 17,887 shares valued at approximately $2.44 million. Institutional investors collectively own 97.64% of RGEN.
• Analysts maintain a bullish outlook, with a consensus “Buy” rating and an average price target of $166.43; three analysts rate the stock Strong Buy and twelve rate it Buy.
• Repligen exceeded quarterly expectations, reporting $0.54 EPS versus the $0.45 consensus and $204.13 million in revenue, up 11.9% year over year. Shares opened at $169.61, near the upper end of their $100.99–$188.73 52-week range.

Van ECK Associates Corp increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 173.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,887 shares of the biotechnology company's stock after purchasing an additional 11,354 shares during the quarter. Van ECK Associates Corp's holdings in Repligen were worth $2,441,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the fourth quarter worth $36,000. Northwestern Mutual Wealth Management Co. acquired a new position in Repligen during the second quarter worth $52,000. Farther Finance Advisors LLC raised its position in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 104 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Citigroup upgraded Repligen to a "buy" rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 13th. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Evercore restated an "outperform" rating and issued a $160.00 price target on shares of Repligen in a research note on Monday, July 6th. Finally, HSBC cut their price target on Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $166.43.

Insider Buying and Selling at Repligen

In related news, CFO Jason Garland sold 733 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.60% of the company's stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $169.61 on Friday. The firm has a market cap of $9.57 billion, a P/E ratio of 232.34, a price-to-earnings-growth ratio of 3.16 and a beta of 1.05. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The business's 50 day moving average is $155.13 and its 200-day moving average is $134.02.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source